When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
REPL - Replimune presents promising data on lead programs RP1 and RP2
Replimune Group Inc.
Replimune's (REPL) on lead programs, RP1 and RP2, demonstrated anti-tumor activity and robust immune response in clinical biomarker studies, according to new preclinical data.The data, presented at the American Association for Clinical Oncology meeting, showed that RP1 in combination with Opdivo (nivolumab) and RP2 alone increased infiltration of CD8+ T cells ands PD-L1 expression for patients.#AACR21Replimune shares closed down 2.4% to $29.35